1. Scrip

First-To-Market Calliditas Picking Up Speed In IgA Nephropathy

 
• By Andrew McConaghie

A few hiccups aside, Tarpeyo is on track in the US, but major competition from Novartis is just round the corner.

Calliditas’ IgA nephropathy drug Tarpeyo is picking up speed in the US, despite experiencing some bumps in the road in the first quarter.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business